Metsera, Inc. aims to raise $275 million in an IPO to fund its clinical-stage biopharma programs targeting obesity and ...

Related Group and 13th Floor Investments joined forces to buy an Aventura apartment complex for $96.5 million.

The word on San Francisco’s famously hilly streets is that big pharma is ready to go shopping in 2025, following a flurry of ...

Reports suggest that markets are projected to bounce back, making 2025 one of the strongest years in recent memory for ...

Brendan Wallace has a lot on his mind lately. Wallace is the co-founder of Fifth Wall Ventures, a 9-year-old proptech venture firm with $3.2 billion in ...

Biotech company Metsera, which develops weight-loss drugs and is backed by ARCH Venture Partners, said on Monday that it is ...

Metsera Inc. is seeking to raise $292 million in an initial public offering, joining a clutch of health-care firms set to ...

Metsera has set its sights on a hefty $289 million IPO as the next-gen obesity biotech seeks to fund a phase 3 trial of its ...

Weight-loss drug developer Metsera is targeting an up to $1.78 billion valuation in its initial public offering, the ARCH Venture Partners-backed biotech company said on Monday. New York City-based ...

AI expert Kevin Novak was no stranger to hype.

ARCH is one of the leading U.S. producers of high-quality metallurgical coal (“met coal”). This is the kind of coal used for ...

The deal would value the firm at about $2 billion and mark the latest push by private equity into the industry.